FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bi	urden								

0.5

hours per response:

Г

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

											,								
Name and Address of Reporting Person* Paylogy Carroles						2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS INC [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Barlow Carrolee						SUPN]								X Direct	or		10% Ow	vner	
(Last) (First) (Middle)				_	5677.]									r (give title)		Other (s below)	specify		
C/O SUPERNUS PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year)													
1550 EAST GUDE DRIVE					06	06/27/2018													
1550 EAST GODE DRIVE						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)													Lin	,					
ROCKV	ILLE N	ИD	20850												•		orting Persor		
					_									Form Perso		e than	One Repor	rting	
(City)	(:	State)	(Zip)																
						_			·			, -	<i>c</i>		•				
		Iar	ole I - Noi	n-Deriv	vativ	e Se	curities	S AC	quired, D	oisp				ly Owne	<u> </u>				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ear)	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Disposed Code (Instr. 5)		ties Acquire d Of (D) (Ins	ed (A) or str. 3, 4 and	Benefic	es F ally (Form (D) o	: Direct	7. Nature of Indirect Beneficial Ownership		
						1					(A) or D		Reporte Transac	d	```		(Instr. 4)		
									Code	_	Amount	(D)	Price	(Instr. 3					
			Table II -	Deriva	ative	Sec	urities	Aca	uired, Dis	spo	sed of,	or Ben	eficially	Owned					
									, options										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transactio Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivatives Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Ownership	Beneficial Ownership ct (Instr. 4)	
													Amount or						
					Code	v	(A)	(D)	Date Exercisable		kpiration ate	Title	Number of Shares						
Director		1								T									
Stock Option (Right to	\$58.15	06/27/2018			Α		10,213		(1)	06	5/27/2028	Common Stock	10,213	\$0	10,213	3	D		

Explanation of Responses:

1. The option vests in four equal annual installments beginning on June 27, 2019.

/s/ Gregory S. Patrick, as attorney-in-fact

07/02/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.